MyQuest™

RIGLIETTI,ROBERT

DOB: 07/30/1995
Sex: M
Phone: (631) 793-2551
Patient ID: 1109

Age: 29
Fasting: Y

Specimen: ZD710963E
Requisition: 0000763
Lab Reference ID: 3965
Report Status: FINAL / SEE REPORT

Collected: 06/03/2025 15:00
Received: 06/03/2025 15:10
Reported: 06/10/2025 14:08

Client #: 91436084
SHILIAN,RYAN
ALLERGY IMMUNOLOGY CTR
STE 409
16661 VENTURA BLVD
ENCINO, CA 91436-1914
Phone: (818) 514-3544
Fax: (818) 578-0298

FASTING:YES ; COLLECTION KIT GIVEN TO PATIENT. PATIENT ADVISED TO RETURN.

⚠ HISTAMINE, PLASMA

Analyte	Value	
⚠ HISTAMINE, PLASMA	9.4 H	Reference Range: < OR = 1.8 ng/mL

This test was performed using a kit that has not been cleared or approved by the FDA. The analytical performance characteristics of this test have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. This test should not be used for diagnosis without confirmation by other medically established means.

⚠ MANNAN BINDING LECTIN PATHWAY FUNCTION (C4B)

Analyte	Value	
⚠ MANNAN BINDING LECTIN PATHWAY FUNCTION (C4B)	<52.0 L	Reference Range: >200 ng/mL

The reference range was determined with sera from a population of known deficient patients. A value below 200 ng/mL indicates the patient is deficient in either MBL, MASP-2, or both. A normal healthy population has a lower 95% percentile cutoff of 676 ng/mL.

*This test was developed and its performance characteristics determined by Eurofins Viracor. It has not been cleared or approved by the U.S. Food and Drug Administration.

FLAG Interpretation: A = Abnormal, H = High, L = Low

⚠ PROSTAGLANDINS D2 (RANDOM URINE)

Analyte	Value	
SPECIMEN TYPE/CONTAINER:	Urine/Cup	
⚠ PGD2 (RANDOM URINE)	260 H	Reference Range: <175 ng/g Creatinine

This test has not been cleared or approved by the US Food and Drug Administration.

This test was developed and its performance characteristics determined by Inter Science Institute. Values obtained with different methods, laboratories, or kits cannot be used interchangeably with the results on this report. The results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

⚠ RESPIRATORY ALLERGY PROFILE REGION XIII

Analyte	Value	
DERMATOPHAGOIDES PTERONYSSINUS (D1) IGE	<0.10	kU/L
CLASS	0	

DERMATOPHAGOIDES FARINAE (D2) IGE	**<0.10**	kU/L
CLASS	**0**	
PENICILLIUM NOTATUM (M1) IGE	**<0.10**	kU/L
CLASS	**0**	
CLADOSPORIUM HERBARUM (M2) IGE	**<0.10**	kU/L
CLASS	**0**	
ASPERGILLUS FUMIGATUS (M3) IGE	**<0.10**	kU/L
CLASS	**0**	
ALTERNARIA ALTERNATA (M6) IGE	**<0.10**	kU/L
CLASS	**0**	
CAT DANDER (E1) IGE	**<0.10**	kU/L
CLASS	**0**	
DOG DANDER (E5) IGE	**<0.10**	kU/L
CLASS	**0**	
⚠ **COCKROACH (I6) IGE**	**0.15 H**	kU/L
CLASS	**0/1**	
ALDER (T2) IGE	**<0.10**	kU/L
CLASS	**0**	
MOUNTAIN CEDAR (T6) IGE	**<0.10**	kU/L
CLASS	**0**	
OLIVE TREE (T9) IGE	**<0.10**	kU/L
CLASS	**0**	
WALNUT TREE (T10) IGE	**<0.10**	kU/L
CLASS	**0**	
COTTONWOOD (T14) IGE	**<0.10**	kU/L
CLASS	**0**	
OAK (T7) IGE	**<0.10**	kU/L
CLASS	**0**	
ELM (T8) IGE	**<0.10**	kU/L
CLASS	**0**	
WHITE MULBERRY (T70) IGE	**<0.10**	kU/L
CLASS	**0**	
BERMUDA GRASS (G2) IGE	**<0.10**	kU/L
CLASS	**0**	
TIMOTHY GRASS (G6) IGE	**<0.10**	kU/L
CLASS	**0**	
JOHNSON GRASS (G10) IGE	**<0.10**	kU/L
CLASS	**0**	

COMMON RAGWEED (SHORT) (W1) IGE	**<0.10**	kU/L
CLASS	**0**	
MUGWORT (W6) IGE	**<0.10**	kU/L
CLASS	**0**	
RUSSIAN THISTLE (W11) IGE	**<0.10**	kU/L
CLASS	**0**	
ROUGH PIGWEED (W14) IGE	**<0.10**	kU/L
CLASS	**0**	
MOUSE URINE PROTEINS (E72) IGE	**<0.10**	kU/L
CLASS	**0**	
IMMUNOGLOBULIN E	**101**	Reference Range: <OR=114 kU/L

INTERPRETATION

Analyte	Value
INTERPRETATION	

```
Specific                        Level of Allergen
IGE Class       kU/L            Specific IGE Antibody
 -----          ---------       -------------------
  0               <0.10          Absent/Undetectable
  0/1         0.10-0.34          Very Low Level
  1           0.35-0.69          Low Level
  2           0.70-3.49          Moderate Level
  3           3.50-17.4          High Level
  4           17.5-49.9          Very High Level
  5             50-100           Very High Level
  6               >100           Very High Level

The clinical relevance of allergen results of
0.10-0.34 kU/L are undetermined and intended for
specialist use.

Allergens denoted with a "**" include results using
one or more analyte specific reagents. In those
cases, the test was developed and its analytical
performance characteristics have been determined by
Quest Diagnostics. It has not been cleared or approved
by the U.S. Food and Drug Administration. This assay
has been validated pursuant to the CLIA regulations
and is used for clinical purposes.
```

N METHYLTHISTAMINE, RANDOM, U

Analyte	Value	
N METHYLHISTAMINE, RANDOM, U	**95**	Reference Range: 30-200 mcg/g Cr

```
-------------------ADDITIONAL INFORMATION-------------------
This test was developed and its performance characteristics
determined by Mayo Clinic in a manner consistent with CLIA
requirements. This test has not been cleared or approved by
the U.S. Food and Drug Administration.
```

CREATININE, RANDOM, U	**100**	Reference Range: 16 - 326 mg/dL

TRYPTASE

Analyte	Value

TRYPTASE The Tryptase test, fluorescent enzyme immunoassay (FEIA), measures both the Alpha and Beta forms of Tryptase. Measuring both forms of Tryptase increases sensitivity for the diagnosis of mastocytosis, and mast cell degranulation as a cause of anaphylaxis.	**6.1**	Reference Range: <11.0 mcg/L

IMMUNOGLOBULINS

Analyte	Value	
IMMUNOGLOBULIN A	**297**	Reference Range: 47-310 mg/dL
IMMUNOGLOBULIN G	**1055**	Reference Range: 600-1640 mg/dL
IMMUNOGLOBULIN M	**112**	Reference Range: 50-300 mg/dL

STREPTOCOCCUS PNEUMONIAE AB (IGG) (23 SEROTYPES)

Analyte	Value
SEROTYPE 1 (1)	**0.6**
SEROTYPE 2 (2)	**5.5**
SEROTYPE 3 (3)	**0.6**
SEROTYPE 4 (4)	**<0.3**
SEROTYPE 5 (5)	**2.6**
SEROTYPE 8 (8)	**6.1**
SEROTYPE 9 (9N)	**2.8**
SEROTYPE 12 (12F)	**<0.3**
SEROTYPE 14 (14)	**<0.3**
SEROTYPE 17 (17F)	**0.9**
SEROTYPE 19 (19F)	**1.8**
SEROTYPE 20 (20)	**3.0**
SEROTYPE 22 (22F)	**2.4**
SEROTYPE 23 (23F)	**<0.3**
SEROTYPE 26 (6B)	**<0.3**
SEROTYPE 34 (10A)	**<0.3**
SEROTYPE 43 (11A)	**1.8**
SEROTYPE 51 (7F)	**1.0**
SEROTYPE 54 (15B)	**0.9**
SEROTYPE 56 (18C)	**0.3**
SEROTYPE 57 (19A)	**5.9**
SEROTYPE 68 (9V)	**2.9**

SEROTYPE 70 (33F)	**0.5**

Serologic correlates of protection against pneumococcal disease have not been rigorously established for all patient populations. Published data and expert consensus (including WHO) suggest protection from invasive disease usually occurs at levels >or =0.3-0.50 mcg/mL for healthy children receiving pneumococcal conjugate vaccines. Higher titers may be necessary to protect from non-invasive infection (e.g., pneumonia, otitis, sinusitis). Expert opinion suggests that a cut-off of >= 1.3 mcg/mL may be a more relevant value to assess antibody responses after pneumococcal polysaccharide vaccines or for immunocompromised patients. In addition to antibody quantity, protection also depends on antibody avidity and opsonophagocytic activity. Some experts consider that post-vaccination (4-6 weeks) IgG seroconversion and/or 2- to 4-fold rise in IgG titers for >50% to 70% of vaccine serotypes demonstrates a normal post-vaccine serologic response. Persons with high initial serotype-specific titers may have less robust responses.

Quest Diagnostics uses a multi-analyte immunodetection (MAID) method. The method employs the Luminex flow cytometric system which measures multiple analytes simultaneously. The FDA standard reference serum 89-S is used as the calibration standard. Results are reported in mcg/mL.

This assay detects all of the 23 of the serotypes in the 23-valent polysaccharide vaccine and 12 of the 13 serotypes in the 13-valent conjugate vaccine.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and used for clinical purposes.

For additional information, please refer to http://education.questdiagnostics.com/faq/FAQ181 (This link is being provided for informational/ educational purposes only.)

Performing Sites

ACER Eurofins Viracor, 18000 W 99Th Street, Lenexa, KS 66219-1233 Laboratory Director: Brock Neil PhD BCLD (ABB)
EN Quest Diagnostics-West Hills, 8401 Fallbrook Ave, West Hills, CA 91304-3226 Laboratory Director: Thomas J McDonald
EO Mayo Clinic Laboratories, 200 First Street SW, Rochester, MN 55905-1770 Laboratory Director: Nikola A Baumann M.D. Ph.D.
EZ Quest Diagnostics/Nichols SJC-San Juan Capistrano,, 33608 Ortega Hwy, San Juan Capistrano, CA 92675-2042 Laboratory Director: Irina Maramica MD,PhD,MBA
INS INTERSCIENCE INSTITUTE, 944 W Hyde Park Blvd, Inglewood, CA 90302-3308 Laboratory Director: James Lee MD,PhD
MYM Mayo Clinic Laboratories, 3050 Superior Dr Nw, Rochester, MN 55905-1770 Laboratory Director: Nikola A Baumann M.D. Ph.D.

Key

Priority Out of Range Out of Range